Instadose Pharma Corp.
INSD
$0.00
$0.000.00%
OTC PK
| 02/28/2022 | 02/28/2021 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 524.50K | 10.08M | |||
| Depreciation & Amortization | 360.50K | 359.40K | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 885.00K | 10.44M | |||
| Operating Income | -885.00K | -10.44M | |||
| Income Before Tax | -906.30K | -10.43M | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -906.30K | -10.43M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -906.30K | -10.43M | |||
| EBIT | -885.00K | -10.44M | |||
| EBITDA | -524.50K | -10.08M | |||
| EPS Basic | 0.00 | -0.02 | |||
| Normalized Basic EPS | 0.00 | -0.01 | |||
| EPS Diluted | 0.00 | -0.02 | |||
| Normalized Diluted EPS | 0.00 | -0.01 | |||
| Average Basic Shares Outstanding | 531.93M | 501.42M | |||
| Average Diluted Shares Outstanding | 531.93M | 501.42M | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||